Figure 2.

Relative proportion of functional CMV-specific T-cell phenotypes. The proportion of CMV-specific CD4⁺ (A) and CD8⁺ (B) T-cell subset phenotypes based on the total number of functional markers expressed at approximately day 90 after HCT in letermovir recipients and preemptive therapy recipients. Responses were measured after stimulation with CMV IE-1, pp65, or SEB (positive control). Granzyme B monofunctional cytokine responses were excluded from these charts, as some cell subsets have been noted to express this cytokine constitutively (see "Letermovir is associated with decreased CMV-specific polyfunctional responses").